News Results for e-Therapeutics (ETX)

  • 10 Dec
    08:20
    E-therapeutics agrees to work with Novo Nordisk to discover potential type-2 diabetes treatments

    E-therapeutics said Monday it had agreed a research collaboration with Novo Nordisk under which the companies would use e-therapeutics' proprietary Network-Driven Drug Discovery platform to look to...

  • 09 Aug
    09:00
    Director Deals - e-Therapeutics PLC (ETX)

    Steve Medlicott, Executive Director, bought 100,000 shares in the company on the 8th August 2018 at a price of 7.00p. The Director now holds 1,550,000 shares. Story provided by...

  • 07 Aug
    09:00
    Director Deals - e-Therapeutics PLC (ETX)

    Iain Ross, Chairman, bought 250,000 shares in the company on the 3rd August 2018 at a price of 6.50p. The Director now holds 1,700,000 shares. Story provided by StockMarketWire.com Director...

  • 03 Jul
    15:20
    Director Deals - e-Therapeutics PLC (ETX)

    Prof Trevor Jones, Non Executive Director, bought 74,526 shares in the company on the 2nd July 2018 at a price of 7.38p. The Director now holds 396,247 shares. Story provided by...

  • 27 Mar
    08:41
    e-Therapeutics operating losses narrow as R&D spend shrinks

    e-Therapeutics said operating losses narrowed to £6.8m in the year to the end of January, from £16.3m in 2016, buoyed by a fall in R&D spend. The reduction in operating losses was mainly...

  • 15 Jan
    08:26
    e-Therapeutics enters two AI collaborations

    e-Therapeutics is to collaborate with Intellegens and Biorelate to enhance and extend its artificial intelligence technology capabilities. e-Therapeutics said both companies had artificial...

  • 18 Dec
    11:05
    Director Deals - e-Therapeutics PLC (ETX)

    Iain Ross, Chairman, bought 200,000 shares in the company on the 15th December 2017 at a price of 8.90p. The Director now holds 1,450,000 shares. Story provided by StockMarketWire.com Director...

  • 18 Dec
    11:05
    Director Deals - e-Therapeutics PLC (ETX)

    Dr Raymond Barlow, Chief Executive Officer, bought 100,000 shares in the company on the 15th December 2017 at a price of 8.90p. The Director now holds 1,200,000 shares. Story provided by...

  • 18 Dec
    11:05
    Director Deals - e-Therapeutics PLC (ETX)

    Steve Medlicott, Executive Director, bought 200,000 shares in the company on the 15th December 2017 at a price of 8.90p. The Director now holds 1,450,000 shares. Story provided by...

  • 18 Dec
    11:05
    Director Deals - e-Therapeutics PLC (ETX)

    Prof Trevor Jones, Non Executive Director, bought 50,000 shares in the company on the 15th December 2017 at a price of 8.90p. The Director now holds 262,261 shares. Story provided by...

  • 18 Dec
    11:05
    Director Deals - e-Therapeutics PLC (ETX)

    Christine Soden, Non Executive Director, bought 120,000 shares in the company on the 15th December 2017 at a price of 8.90p. The Director now holds 120,000 shares. Story provided by...

  • 01 Nov
    09:30
    e-Therapeutics unveils board changes

    e-Therapeutics has announced the appointment of Christine Soden as non-executive director, and the retirement of Brad Hoy who has served on the board as a non-executive director for nine years....

  • 05 Sep
    09:47
    e-therapeutics schedules interims

    e-therapeutics will announce its results for the six months ended 31 July on 26 September. At 9:47am: (LON:ETX) eTherapeutics PLC share price was 0p at 10.75p Story provided by...

  • 22 Aug
    16:10
    Director Deals - e-Therapeutics PLC (ETX)

    Iain Ross, Chairman, bought 250,000 shares in the company on the 22nd August 2017 at a price of 10.60p. The Director now holds 1,250,000 shares. Story provided by StockMarketWire.com Director...

  • 22 Aug
    16:10
    Director Deals - e-Therapeutics PLC (ETX)

    Iain Ross, Chairman, bought 250,000 shares in the company on the 22nd August 2017 at a price of 10.60p. The Director now holds 1,250,000 shares. Story provided by StockMarketWire.com Director...

  • 28 Jul
    08:29
    Edison issues update on e-Therapeutics

    Edison has issued an update on e-Therapeutics following the business and strategic review undertaken by new chief executive Ray Barlow since joining the company in April. Edison said: "The...

  • 24 Jul
    09:57
    e-Therapeutics completes 'root and branch' review

    e-Therapeutics has completed a 'root and branch' strategic review which, it said, had confirmed the novelty, utility and productivity of its network-driven drug discovery (NDD) platform. It...

  • 03 Jul
    17:00
    Director Deals - e-Therapeutics PLC (ETX)

    Prof Trevor Jones, Non Executive Director, bought 45,364 shares in the company on the 3rd July 2017 at a price of 12.13p. The Director now holds 212,261 shares. NOTE: Subscribed for shares. Story...

  • 02 Jun
    11:05
    Director Deals - e-Therapeutics PLC (ETX)

    Iain Ross, Chairman, bought 1,000,000 shares in the company on the 1st June 2017 at a price of 6.00p. The Director now holds 1,000,000 shares. Story provided by StockMarketWire.com Director...

  • 02 Jun
    11:05
    Director Deals - e-Therapeutics PLC (ETX)

    Dr Raymond Barlow, Chief Executive Officer, bought 830,000 shares in the company on the 1st June 2017 at a price of 6.00p. The Director now holds 830,000 shares. Story provided by...

  • 02 Jun
    11:05
    Director Deals - e-Therapeutics PLC (ETX)

    Steve Medlicott, Financial Director, bought 1,000,000 shares in the company on the 1st June 2017 at a price of 6.00p. The Director now holds 1,250,000 shares. Story provided by...

  • 31 May
    14:05
    All resolutions passed at AGM of e-Therapeutics

    e-Therapeutics has confirmed that all resolutions were passed by shareholders at the Annual General Meeting of the Company held earlier today. At 2:05pm: (LON:ETX) eTherapeutics PLC share price...

  • 23 May
    17:25
    Director Deals - e-Therapeutics PLC (ETX)

    Prof Trevor Jones, Non Executive Director, bought 59,400 shares in the company on the 12th May 2017 at a price of 8.25p. The Director now holds 166,897 shares. Story provided by...

  • 19 Apr
    07:47
    e-Therapeutics operating losses rise

    e-Therapeutics' operating losses rose to £16.3m in the year to the end of January - up from £11.55m. The figure included impairment of goodwill and intangibles of £2.8m (FY16: £nil). The group...

  • 19 Apr
    07:12
    FLASH: e-Therapeutics operating losses rise

    Story provided by StockMarketWire.com

  • 09 Jan
    07:30
    e-Therapeutics appoints CEO

    e-Therapeutics has appointed Dr. Raymond Barlow as chief executive. He will take up the role on or before 1 May, at which point he will be appointed to the e-Therapeutics board. Barlow, aged...

  • 09 Jan
    07:06
    FLASH: e-Therapeutics appoints CEO

    Story provided by StockMarketWire.com

  • 04 Jan
    09:45
    Director Deals - e-Therapeutics PLC (ETX)

    Prof Trevor Jones, Non Executive Director, received in lieu of fees/salary 36,917 shares in the company on the 3rd January 2017 at a price of 7.45p. The Director now holds 107,497 shares. NOTE:...

  • 06 Oct
    10:25
    Director Deals - e-Therapeutics PLC (ETX)

    Prof Trevor Jones, Non Executive Director, bought 41,204 shares in the company on the 5th October 2016 at a price of 11.33p. The Director now holds 70,580 shares. NOTE: Subscription. Story...

  • 20 Sep
    07:27
    e-Therapeutics operating losses rise

    e-Therapeutics posts an operating loss of £9.7m for the six months to the end of July (HY15: loss of £5.9m), including £2.1m goodwill write-off from the Searchbolt acquisition in May. The...

  • 20 Sep
    07:02
    FLASH: e-Therapeutics operating losses rise

    Story provided by StockMarketWire.com

  • 09 Sep
    09:46
    e-Therapeutics schedules interims

    e-Therapeutics, the drug discovery company, will announce its half year results for the six months ended 31 July on 20 September. At 9:46am: (LON:ETX) eTherapeutics PLC share price was 0p at...

  • 25 May
    15:07
    e-Therapeutics resolutions passed at AGM

    e-Therapeutics has confirmed that all resolutions proposed at the annual general meeting today were passed. At 3:07pm: (LON:ETX) eTherapeutics PLC share price was +1p at 14.25p Story provided...

  • 25 May
    08:17
    e-Therapeutics encouraged by progress

    e-Therapeutics is encouraged by the progress and scope of its antiviral programme while two of its most advanced projects are approaching lead candidate selection, shareholders at the annual...

  • 25 May
    07:12
    FLASH: e-Therapeutics encouraged by progress

    Story provided by StockMarketWire.com

  • 12 May
    14:45
    Director Deals - e-Therapeutics PLC (ETX)

    Prof Trevor Jones, Non Executive Director, bought 29,376 shares in the company on the 11th May 2016 at a price of 19.14p. The Director now holds 29,376 shares. NOTE: Subscription for new shares....

  • 11 May
    07:53
    e-Therapeutics to acquire Searchbolt

    e-Therapeutics, the drug discovery company, has proposed the acquisition of Searchbolt Limited, for an initial consideration of up to GBP2.32m. e-Therapeutics is focused on commercialising and...

  • 11 May
    07:18
    FLASH: e-Therapeutics to acquire Searchbolt

    Story provided by StockMarketWire.com

  • 15 Apr
    12:35
    e-Therapeutics schedules AGM

    e-Therapeutics has confirmed that the Company's 2016 AGM will take place at 12:30pm on 25 May 2016 at the offices of Bond Dickinson LLP, 4 More London Riverside, London, SE1 2AU. At 12:35pm:...

  • 22 Mar
    08:14
    e-Therapeutics operating losses rise

    Drug discovery and development company e-Therapeutics posts an operating loss of GBP11.6m for the year to the end of January - up from GBP10.2m last time. The overall expenditure on research and...

  • 22 Mar
    07:21
    FLASH: e-Therapeutics operating losses rise

    Story provided by StockMarketWire.com

  • 04 Mar
    08:48
    e-Therapeutics schedules FY results

    e-Therapeutics, the drug discovery and development company, will announce its results for the year ended 31 January on 22 March. At 8:48am: (LON:ETX) eTherapeutics PLC share price was -0.75p at...

  • 15 Feb
    13:48
    e-Therapeutics antidepressant misses target

    e-Therapeutics is to carry out further analysis of data from the phase IIb trial of its antidepressant ETS6103 which did not meet the primary endpoint of establishing non-inferiority when compared...

  • 06 Jan
    07:54
    e-Therapeutics appoints non-executive chairman

    e-Therapeutics has appointed Iain Ross as non-executive chairman. Professor Malcolm Young now steps down as acting chairman and continues his role as chief executive. Ross has over 35 years'...

  • 06 Jan
    07:16
    FLASH: e-Therapeutics appoints non-executive chairman

    Story provided by StockMarketWire.com

  • 17 Sep
    09:37
    e-Therapeutics appoints Nomad

    e-Therapeutics has appointed Numis Securities as its nominated adviser and broker with immediate effect. At 9:37am: (LON:ETX) eTherapeutics PLC share price was 0p at 32.25p Story provided by...

  • 17 Sep
    08:04
    e-Therapeutics schedules interims

    e-Therapeutics, the drug discovery and development company, will announce its results for the six months ended 31 July on 29 September. At 8:04am: (LON:ETX) eTherapeutics PLC share price was 0p...

  • 17 Aug
    07:48
    e-Therapeutics encouraged by H1 performance

    Drug discovery and development company e-Therapeutics says its discovery platform continues to exceed its expectations. A trading update says: "During H1, we commenced four new projects and...

  • 17 Aug
    07:12
    FLASH: e-Therapeutics encouraged by H1 performance

    Story provided by StockMarketWire.com

  • 11 Jun
    08:02
    e-Therapeutics expects another exciting year

    e-Therapeutics expects another exciting year, shareholders at the annual general meeting later today will be told. Chairman and chief executive Professor Malcolm Young will say that the company...

  • 11 Jun
    07:13
    FLASH: e-Therapeutics expects another exciting year

    Story provided by StockMarketWire.com

  • 21 May
    09:18
    e-Therapeutics progress in cancer drug study

    e-Therapeutics has confirmed that the first patient has been enrolled in its phase 1b programme for its cancer drug, ETS2101. The first patient received the initial dose on 19 May and will be...

  • 07 May
    08:39
    e-Therapeutics schedules AGM

    e-Therapeutics will hold its annual general meeting at the offices of Bond Dickinson LLP, St Ann's Wharf, 112 Quayside, Newcastle upon Tyne, NE1 3DX, on 11 June at 10.30 a.m. At 8:39am:...

  • 31 Mar
    07:43
    e-Therapeutics pre-tyax losses rise

    e-Therapeutics, the drug discovery and development company, posts a pre-tax loss of £9.8m for the year to the end of January - up from £6.1m last time. The group said it had cash and liquid...

  • 31 Mar
    07:18
    FLASH: e-Therapeutics pre-tyax losses rise

    Story provided by StockMarketWire.com

  • 26 Feb
    14:09
    e-Therapeutics notes share price rise

    e-Therapeutics, the drug discovery and development company, has noted the recent rise in its share price. It confirmed it has continued to see high levels of productivity through the application...

  • 21 Jan
    12:05
    Director Deals - e-Therapeutics PLC (ETX)

    Steve Medlicott, Financial Director, bought 150,000 shares in the company on the 21st January 2015 at a price of 25.25p. The Director now holds 250,000 shares. Story provided by...

  • 07 Jan
    09:54
    e-Therapeutics issues shares in part lieu of fees

    e-Therapeutics has issued 40,948 new ordinary shares to Professor Oliver James, who retired as non-executive chairman on 31 December, in part lieu of his fees. The new shares were issued yesterday...

  • 05 Jan
    07:41
    e-Therapeutics CEO appointed acting chairman

    e-Therapeutics chief executive Professor Malcolm Young has assumed the role of acting chairman with effect from 1 January. This follows the retirement of chairman and non-executive director...

  • 05 Jan
    07:10
    FLASH: e-Therapeutics appoints acting chairman

    Story provided by StockMarketWire.com

  • 19 Dec
    07:43
    e-Therapeutics' impact rated 'world class'

    The impact of e-Therapeutics' drug discovery activities has been rated 'world class' by the UK's National Research and Impact Assessment exercise. The impact case study on e-Therapeutics was...

  • 19 Dec
    07:03
    FLASH: e-Therapeutics' Impact is rated 'world class'

    Story provided by StockMarketWire.com

  • 18 Dec
    07:47
    e-Therapeutics update on studies

    e-Therapeutics says the maximum tolerated dose (MTD) has been defined in the current UK trial Phase 1a advanced solid tumour study for ETS2101, the company's clinical stage anti-cancer asset....

  • 18 Dec
    07:07
    FLASH: e-Therapeutics update on studies

    Story provided by StockMarketWire.com

  • 27 Nov
    09:56
    e-Therapeutics gives R&D presentation

    e-Therapeutics, the drug discovery and development company, is holding an investor and analyst presentation and workshop today at its Oxford site. The purpose of the site visit is to provide an...

  • 16 Oct
    08:51
    e-Therapeutics appoints executive director

    e-Therapeutics, the drug discovery and development company, is appointing Sean Nicolson, to the board as an executive director. The appointment is expected to become effective in 2015 following...

  • 16 Sep
    07:35
    e-Therapeutics operating losses rise

    e-Therapeutics' first half operating loss was £5.3m (six months to 31 July 2013: loss of £3.1m), as spend increased in both the Discovery and Development activities within the business. Net...

  • 16 Sep
    07:04
    FLASH: e-Therapeutics losses rise

    Story provided by StockMarketWire.com

  • 04 Sep
    15:08
    e-Therapeutics schedules interims

    e-Therapeutics, the drug discovery and development company with a proprietary platform in network pharmacology, will be announcing its half year results for the period ended 31 July on 16...

  • 25 Jun
    17:45
    Director Deals - e-Therapeutics PLC (ETX)

    Prof Oliver James, Chairman, received in lieu of fees/salary 9,819 shares in the company on the 25th June 2014 at a price of 27.50p. The Director now holds 136,235 shares. NOTE: Part fees. Story...

  • 25 Jun
    17:45
    Director Deals - e-Therapeutics PLC (ETX)

    Dr Rajesh Chopra, Non Executive Director, received in lieu of fees/salary 6,736 shares in the company on the 25th June 2014 at a price of 27.50p. The Director now holds 25,799 shares. NOTE: Part...

  • 12 May
    08:12
    e-Therapeutics losses rise

    e-Therapeutics posts a pre-tax loss of £6.1m for the year to the end of January - up from £5.0m last time. Revenue was nil - unchanged from a year ago - and research and development expenditure...

  • 12 May
    07:18
    FLASH: e-Therapeutics pre-tax losses rise

    Story provided by StockMarketWire.com

  • 08 May
    07:41
    e-Therapeutics resumes recruitment in brain cancer trial

    e-Therapeutics says the US Food and Drug Administration has approved the resumption of recruitment of new patients into the company's investigator-led Phase Ia study of ETS2101 in brain cancer,...

  • 08 May
    07:06
    e-Therapeutics resumes recruitment in brain cancer trial

    Story provided by StockMarketWire.com

  • 07 Apr
    13:12
    e-Therapeutics appoints FD

    e-Therapeutics has appointed Steve Medlicott as finance director. Medlicott joins the management team having previously advised the company in its £40m fundraising in 2013. He is a Chartered...

  • 07 Apr
    12:26
    Chief financial officer leaves e-Therapeutics

    e-Therapeutics has announced that Dr Daniel Elger has resigned as chief financial officer with immediate effect. For the time being e-Therapeutics' finances will be managed by Paul Stockdale, who...

  • 31 Mar
    09:00
    e-Therapeutics reports positive trial results

    e-Therapeutics reports positive interim results from UK phase Ia trial of ETS2101 (dexanabinol) in a variety of solid tumours It says ETS2101 was found to be well tolerated at all doses by all...

  • 31 Mar
    07:01
    FLASH: e-Therapeutics reports positive trial results

    Story provided by StockMarketWire.com

  • 26 Mar
    09:37
    e-Therapeutics resumes cancer trial recruitment

    e-Therapeutics has received approval from MHRA to recommence recruitment of new patients into the ETS2101 phase Ia solid tumours trial being conducted at three centres in the UK. Recruitment was...

  • 26 Mar
    07:33
    FLASH: e-Therapeutics resumes recruitment for cancer trial

    Story provided by StockMarketWire.com

  • 10 Feb
    07:24
    e-Therapeutics begins phase I study

    e-Therapeutics has dosed the first healthy volunteer in a newly initiated phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101. The phase I study will employ...

  • 10 Feb
    07:03
    FLASH: e-Therapeutics begins phase I study

    Story provided by StockMarketWire.com

  • 24 Jan
    07:38
    e-Therapeutics halts recruitment into cancer trials

    e-Therapeutics has announced a temporary halt of recruitment into ETS2101 cancer trials because of a practical issue with stored drug for the trials. Patients already receiving treatment with...

  • 24 Jan
    07:13
  • 07 Jan
    08:39
    More patients to enrol in e-Therapeutics brain cancer drug trial

    More patients are to be enrolled in a phase-I trial of e-Therapeutics' brain cancer drug, ETS2101. The trial is being carried out by Professor Santosh Kesari, director of neuro-oncology at the...

  • 16 Oct
    08:16
    e-Therapeutics operating losses rise

    e-Therapeutics, the drug discovery and development company, posts operating losses of £3.1m for the six months to the end of July - up from £2.3m last time. Revenues were nil - unchanged from...

  • 16 Oct
    07:20
    FLASH: e-Therapeutics operating losses rise

    Story provided by StockMarketWire.com

  • 19 Sep
    09:10
    e-Therapeutics schedules interims

    e-Therapeutics will announce its interim results for the six months to the end of July on 16 October. At 9:10am: (LON:ETX) share price was 0p at 34.25p Story provided by StockMarketWire.com

  • 01 Aug
    17:05
    Director Deals - e-Therapeutics PLC (ETX)

    Prof Oliver James, Chairman, received in lieu of fees/salary 7,660 shares in the company on the 1st August 2013 at a price of 0.00p. The Director now holds 126,416 shares. Story provided by...

  • 01 Aug
    17:05
    Director Deals - e-Therapeutics PLC (ETX)

    Dr Rajesh Chopra, Non Executive Director, received in lieu of fees/salary 4,445 shares in the company on the 1st August 2013 at a price of 0.00p. The Director now holds 19,063 shares. Story...

  • 21 Jun
    07:33
    e-Therapeutics CFO to present at forum

    e-Therapeutics chief financial officer Dr Daniel Elger will present at a Proactive Investors One2One Forum on 26 June in Manchester. The event will take place at the Midland Hotel, Peter Street,...

  • 21 Jun
    07:09
    FLASH: e-Therapeutics to present at forum

    Story provided by StockMarketWire.com

  • 14 May
    08:46
    e-Therapeutics net losses rise

    e-Therapeutics posts a net loss of £4.2m for the year to the end of January - up from £3.2m in 2012. The company says this reflects increasing investment in drug discovery and development...

  • 14 May
    07:23
    FLASH: e-Therapeutics net losses rise

    Story provided by StockMarketWire.com

  • 01 Mar
    08:04
    e-Therapeutics completes placing

    e-Therapeutics has completed its £40m placing which was approved by shareholders on 27 February. The company said that following the first placing of 4,750,000 ordinary shares yesterday (28...

  • 01 Mar
    07:18
    FLASH: e-Therapeutics completes placing

    Story provided by StockMarketWire.com

  • 28 Feb
    12:05
    e-Therapeutics completes first placing

    e-Therapeutics (AIM: ETX) yesterday gained shareholder approval to raise £40m by issuing new equity through two share placings. The company has announced that the first placing of 4,750,000 new...

  • 15 Feb
    15:10
    Director Deals - e-Therapeutics PLC (ETX)

    Dr Daniel Elger, Financial Director, bought 15,000 shares in the company on the 15th February 2013 at a price of 32.00p. The Director now holds 30,000 shares. Story provided by...

  • 14 Feb
    13:30
    Director Deals - e-Therapeutics PLC (ETX)

    Steve Self, Executive Director, bought 20,000 shares in the company on the 13th February 2013 at a price of 32.50p. The Director now holds 273,577 shares. Story provided by StockMarketWire.com...

MoneyAM.com

MoneyAM

MoneyAM website is aimed at investors of all levels of experience including City professionals, investors and full-time traders.

  • Free live share prices
  • Free live watch lists
  • UK and Worldwide Indices
  • Live market News
  • Company Fundamentals
  • Charts - Intraday and historic
  • Stock Portfolio

Shares Magazine

Shares Magazine

Shares is the leading weekly publication for high net worth private investors and stock market professionals and as such is read weekly by thousands of private investors, analysts, fund managers, stockbrokers and company directors.

Special offer of 1 month for £1

Fantasy Investor

Fantasy Investor

Come and play Fantasy Investor and learn how to invest and see how much money you can make in shares, funds and ETFs without risking a penny. Play against other investors and build teams to compete in individual and team leagues.

Investor Events

Investor Events

Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.

Terms & Conditions | Privacy Policy | Cookies